KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要